Here’s why we don’t have a cold vaccine. Yet.

MIT
MIT 3M
Researchers are investigating the possibility of a vaccine for the common cold, which affects millions annually. This matters as colds lead to significant economic costs and health disruptions.
Here’s why we don’t have a cold vaccine. Yet.
A What happened
With the onset of cold season, the quest for a vaccine against the common cold has resurfaced. Colds are caused by various viruses, predominantly rhinoviruses, with around 280 variants complicating vaccine development. Previous attempts to create a cold vaccine in the 1960s and 70s were unsuccessful, and interest has waned since then. However, the economic impact of colds, estimated at $40 billion annually in the U.S., highlights the need for effective prevention. Some researchers are exploring ways to bolster immune responses in at-risk populations, while others have made strides in animal studies. Despite the challenges, there remains cautious optimism about the potential for a cold vaccine in the future.

Why it matters

  • Complexity of cold viruses: Over 280 variants of cold-causing viruses complicate vaccine development.

  • Economic impact of colds: Colds cost the U.S. economy approximately $40 billion annually.

  • Research progress: Some scientists are developing strategies to protect vulnerable populations from cold viruses.

  • Historical vaccine attempts: Previous efforts to create a cold vaccine in the 1960s and 70s were unsuccessful.

Topics

Science & Research Research Health & Medicine Medicine Public Health

Read the full article on MIT

Be prepared — without the noise

Calm, decision-grade intelligence for spotting material changes early — without the noise.

Create Free Account Sign In

DECISION-GRADE INTELLIGENCE

Get decision-grade intelligence in your inbox

A high-signal brief covering what changed — and what matters — delivered by email.

A handful of briefs — before your coffee gets cold.

No spam. Unsubscribe anytime. We don’t sell your email.